Modified polysaccharide materials that bind electrolyte cations to deliver salts without increasing salty taste perception. Based on sodium alginate functionalized with chelating groups or peptides, this technology enables tasteless delivery of sodium, potassium, magnesium, and calcium for food, beverage, and nutrition applications.
This technology addresses a common challenge in food and nutrition: delivering essential electrolytes such as sodium, potassium, magnesium, and calcium without amplifying salty or metallic taste perception. The solution uses water-soluble polysaccharides, primarily sodium alginate, chemically modified to incorporate cation-chelating functional groups or small peptides. By sequestering a significant proportion of free cations in solution, the material delivers electrolytes while minimizing the sensory impact of saltiness. This enables formulation of reduced-sodium products and tasteless electrolyte supplements for food, beverage, sports nutrition, and clinical applications.
The technology is at an early-to-mid stage of development. The research team at Monash University's BioPRIA Institute has established methods for modifying polysaccharide materials with polymers and small molecules. Prior published work demonstrates the principle that metal chelation reduces salt and bitter taste perception in calcium salts. Ongoing work focuses on optimizing binding affinity, water solubility, and physical properties to produce a functional material suitable for formulation testing in food and beverage systems.
Monash University is a comprehensive public research university and one of Australia’s largest, known for scale, interdisciplinarity, and an applied orientation. Its Melbourne-based technology precinct brings together university laboratories, pilot-scale and prototyping suites, and company R&D groups alongside government research organizations to enable co-development and rapid iteration. Integration with a major hospital network supports clinical trials and translation, while structured industry placements and doctoral partnerships create a robust talent pipeline for corporate R&D. Research is backed by competitive funding from the Australian Research Council, the National Health and Medical Research Council, and state and federal programs that incentivize industry collaboration. A dedicated technology transfer office manages IP, licensing, and startup formation, with pathways to incubation and investment within the precinct.